دورية أكاديمية
Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
| العنوان: | Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. |
|---|---|
| المؤلفون: | Popovic DS; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Novi Sad, Serbia; Medical Faculty, University of Novi Sad, Novi Sad, Serbia., Patoulias D; Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, General Hospital 'Hippokration', Aristotle University of Thessaloniki, Greece. Electronic address: dipatoulias@gmail.com., Popovic LS; Medical Faculty, University of Novi Sad, Novi Sad, Serbia; Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia., Karakasis P; Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, General Hospital 'Hippokration', Aristotle University of Thessaloniki, Greece., Papanas N; Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece., Mantzoros CS; Beth Israel Deaconess Medical Center and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA. |
| المصدر: | Diabetes research and clinical practice [Diabetes Res Clin Pract] 2024 Jul; Vol. 213, pp. 111758. Date of Electronic Publication: 2024 Jun 24. |
| نوع المنشور: | Journal Article; Meta-Analysis; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1993- : Limerick : Elsevier Scientific Publishers Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985- |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 2*/drug therapy , Randomized Controlled Trials as Topic* , Neoplasms*/epidemiology, Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/adverse effects |
| مستخلص: | Background: Tirzepatide has recently been approved for the treatment of type 2 diabetes mellitus (T2DM), based on its impressive effects on glycemia and body weight reduction. We investigated whether tirzepatide affects the risk for cancer in T2DM. Methods: We conducted a meta-analysis of available, up to 1st April 2024, phase 2/3 randomized controlled trials (RCTs) evaluating the use of tirzepatide in T2DM. We set as primary safety endpoint the risk for any type of cancer, while we assessed as secondary endpoints specific cancer types. Subgroup analyses according to the type of comparator were also performed. Results: We included a total of 9 RCTs with a relatively short study duration, ranging from 36 to 72 weeks. Our preliminary evidence suggests that tirzepatide does not increase the risk for any cancer (primary outcome) or any of the specific cancer types (secondary outcomes). Of course, small number of enrolled participants, short study duration and follow-up, along with scarcity of reported events are considered to be main limitations of the present analysis. Conclusions: Preliminary evidence from our analysis suggests that tirzepatide may not affect the risk ofcancer among individuals with T2DM. However, our results should be interpreted with extra caution, based on the several limitations of our "hypothesis-generating" analysis Future, well-designed studies are warranted to answer this important research question. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cancer; Mortali; Tirzepatide; Type 2 diabetes |
| المشرفين على المادة: | 0 (Hypoglycemic Agents) |
| تواريخ الأحداث: | Date Created: 20240626 Date Completed: 20240712 Latest Revision: 20240715 |
| رمز التحديث: | 20240716 |
| DOI: | 10.1016/j.diabres.2024.111758 |
| PMID: | 38925294 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1872-8227 |
|---|---|
| DOI: | 10.1016/j.diabres.2024.111758 |